What pharmacologic therapy is recommended for myocardial bridging?

Pharmacologic Therapy for Myocardial Bridging

Beta-adrenergic blocking agents are the first-line pharmacologic therapy for symptomatic myocardial bridging, with calcium channel blockers and nitrates serving as alternative or add-on options for patients with inadequate symptom control. 1

First-Line Therapy: Beta-Blockers

• Beta-blockers are the cornerstone of medical management for symptomatic myocardial bridging, recommended by the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guidelines specifically for patients with exercise-induced ischemia. 1

• The mechanism of benefit is through negative chronotropic effects (heart rate reduction), which has been demonstrated to improve left ventricular global longitudinal strain in patients with myocardial bridging. 2

• A systematic review and pooled analysis showed that patients treated with beta-blockers were significantly more likely to remain free from angina (meta-regression B -0.6, P = 0.013), with 78.7% of conservatively managed patients remaining symptom-free at median 31-month follow-up. 3

Second-Line and Alternative Therapies

Calcium Channel Blockers

• Calcium channel blockers should be considered as add-on therapy when beta-blockers alone provide inadequate symptom control, or as initial treatment in properly selected patients. 1

• These agents are particularly valuable when coronary spasm is a contributing mechanism, as spastic coronary hyperactivity must be treated with antispasmodic medications rather than invasive interventions. 4

Nitrates

• Long-acting nitrates should be considered as add-on therapy in patients with inadequate control while on beta-blockers and/or calcium channel blockers. 1

• Critical caveat: Some evidence suggests nitrates should be avoided as they may worsen symptoms in certain patients with myocardial bridging, likely due to reflex tachycardia that increases systolic compression. 5

• When used, nitrates are most appropriate for reproducible spasticity that is responsive to nitroglycerin administration during acetylcholine testing. 4

Additional Options

• Nicorandil or trimetazidine may be considered as add-on therapy in patients with inadequate symptom control on beta-blockers and/or calcium channel blockers. 1

• Ivabradine is used as second-line therapy for heart rate control when beta-blockers are contraindicated or not tolerated. 6

Treatment Algorithm

1. Initiate beta-blocker therapy as first-line treatment for symptomatic patients with myocardial bridging and exercise-induced ischemia. 1

2. If symptoms persist, add calcium channel blockers or long-acting nitrates (with caution regarding nitrates potentially worsening symptoms). 1, 5

3. For refractory symptoms, consider adding nicorandil or trimetazidine, or substitute ivabradine if beta-blockers are not tolerated. 1, 6

4. Reserve invasive approaches (surgical unroofing or, less preferably, stenting) only for patients with symptoms refractory to maximally tolerated medical therapy. 3, 6

Important Clinical Considerations

• Medical therapy alone is effective in the majority of cases, with most patients achieving freedom from angina without requiring invasive intervention. 3

• Stenting should generally be avoided as it is associated with high rates of target vessel revascularization (40.07%) and worse outcomes compared to surgical approaches, particularly when stents extend into the myocardial bridge. 3, 7

• Restriction to low-intensity sports should be implemented in symptomatic patients alongside pharmacologic therapy. 1

• The prognosis for isolated myocardial bridging is generally excellent, with major cardiovascular events occurring in only 3.4% of patients during long-term follow-up. 3